Mitsubishi UFJ Trust & Banking Corp Sells 14,700 Shares of Zoetis Inc. $ZTS

Mitsubishi UFJ Trust & Banking Corp trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.4% during the second quarter, Holdings Channel reports. The firm owned 213,961 shares of the company’s stock after selling 14,700 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Zoetis were worth $15,375,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Louisiana State Employees Retirement System acquired a new stake in Zoetis in the 1st quarter valued at $2,542,000. Deutsche Bank AG raised its stake in Zoetis by 19.1% during the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after acquiring an additional 891,921 shares in the last quarter. Pincus Capital Management LP acquired a new position in Zoetis during the fourth quarter worth $2,109,000. Highbridge Capital Management LLC bought a new position in shares of Zoetis during the fourth quarter valued at $7,004,000. Finally, Pacer Advisors Inc. lifted its holdings in shares of Zoetis by 16.7% during the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after acquiring an additional 23,687 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Zoetis stock opened at $73.64 on Friday. The business’s 50-day simple moving average is $76.30 and its 200 day simple moving average is $99.01. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.74. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the business posted $1.76 EPS. The company’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is 34.93%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. UBS Group lowered their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Finally, Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.